Ren M - Search Results

1

Long-term safety of fezolinetant in Chinese women with vasomotor symptoms associated with menopause: the phase 3 open-label MOONLIGHT 3 clinical trial.

Yu Q, Ming F, Ma J, Cai Y, Wang L, Ren M, Zhang J, Ma X, Miyazaki K, He W, Wang X. Yu Q, et al. Among authors: ren m. J Int Med Res. 2024 May;52(5):3000605241246624. doi: 10.1177/03000605241246624. J Int Med Res. 2024. PMID: 38818887 Free PMC article. Clinical Trial.

2

Octreotide is the favorable alternative for cisplatin resistance reversal of ovarian cancer in vitro and in nude mice in vivo.

Shen Y, Ren ML, Shi YH, Zhang YX, Cai YL. Shen Y, et al. Among authors: ren ml. Eur J Gynaecol Oncol. 2012;33(6):584-90. Eur J Gynaecol Oncol. 2012. PMID: 23327050

3

Environmental exposure and risk of uterine leiomyoma: an epidemiologic survey.

Shen Y, Xu Q, Xu J, Ren ML, Cai YL. Shen Y, et al. Among authors: ren ml. Eur Rev Med Pharmacol Sci. 2013 Dec;17(23):3249-56. Eur Rev Med Pharmacol Sci. 2013. PMID: 24338469 Free article.

4

[Survey on characteristics of menopause of Chinese women with the age of 40-60 years at gynecological clinic from 14 hospitals].

Chen R, Yu Q, Xu KH, Xie MQ, Lei XM, Ren ML, Ruan XY, Ding Y, Fu SX, Yang X, Lin Y, Wang HL, Wu YY, Zhang SF, Guo XT. Chen R, et al. Zhonghua Fu Chan Ke Za Zhi. 2013 Oct;48(10):723-7. Zhonghua Fu Chan Ke Za Zhi. 2013. PMID: 24406126 Chinese.

5

[Effects of estrogen replacement therapy on cognitive function of ovariectomized rats].

Liu X, Wang L, Peng D, Wang Y, Ren M. Liu X, et al. Among authors: ren m. Zhonghua Fu Chan Ke Za Zhi. 2014 Jan;49(1):42-7. Zhonghua Fu Chan Ke Za Zhi. 2014. PMID: 24694917 Chinese.

6

Contraceptive efficacy and safety of estradiol valerate/dienogest in a healthy female population: a multicenter, open-label, uncontrolled Phase III study.

Yu Q, Huang Z, Ren M, Chang Q, Zhang Z, Parke S. Yu Q, et al. Among authors: ren m. Int J Womens Health. 2018 Jun 7;10:257-266. doi: 10.2147/IJWH.S157056. eCollection 2018. Int J Womens Health. 2018. PMID: 29922096 Free PMC article.

7

Ultra-low-dose estradiol and dydrogesterone: a phase III study for vasomotor symptoms in China.

Ren M, Ruan X, Gu L, Pexman-Fieth C, Kahler E, Yu Q. Ren M, et al. Climacteric. 2022 Jun;25(3):286-292. doi: 10.1080/13697137.2021.1956894. Epub 2021 Aug 17. Climacteric. 2022. PMID: 34402360 Free article. Clinical Trial.

8

Changes in menopausal symptoms comparing oral estradiol versus transdermal estradiol.

Tang R, Xie Z, Ruan X, Zhang Z, Ren M, Wu J, Shu K, Shi H, Xie M, Lv S, Yang X, Chen R, Yu Q. Tang R, et al. Among authors: ren m. Climacteric. 2024 Apr;27(2):171-177. doi: 10.1080/13697137.2023.2273530. Epub 2023 Nov 9. Climacteric. 2024. PMID: 37942806 Clinical Trial.

9

Evaluating the cost utility of estradiol plus dydrogesterone for the treatment of menopausal women in China.

Tamlyn Anne R, Downes M, Simoncini T, Yu Q, Ren M, Wang Y, Graziano CM, Kim K. Tamlyn Anne R, et al. Among authors: ren m. J Med Econ. 2024 Jan-Dec;27(1):16-26. doi: 10.1080/13696998.2023.2289297. Epub 2023 Dec 11. J Med Econ. 2024. PMID: 38037348 Free article.

10

Efficacy and safety of fezolinetant for moderate to severe vasomotor symptoms associated with menopause among women in East Asia: a phase 3 randomized study (MOONLIGHT I).

Ruan X, Bai W, Ren M, Kim T, Lee JY, Chuang FC, Wang PH, He W, Ma X, Miyazaki K, Song N, Wang X, Yu Q. Ruan X, et al. Among authors: ren m. J Int Med Res. 2024 May;52(5):3000605241247684. doi: 10.1177/03000605241247684. J Int Med Res. 2024. PMID: 38818888 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,176 results

Search Page

Filters